Page 148 - NobleCon20-Book-Project

Health Care
Date November 18, 2024 Health Care
52wk High $13.56
52wk Low $0.21 Silexion Therapeutics Corp SLXN $0.22
The Goldyne Savad Institute of Gene Therapy
Jerusalem, N/A 9112001

(USD - in millions) silexion.com
Market Cap 1.8
Enterprise 17.6
Basic Shares Out. 8.32 COMPANY OVERVIEW
Float 7.29
Institutional Holdings 1.51% Detailed Analysis:Channelchek.com
Short Interest 0.77 Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage,
Avg. 90-Day Volume 2.82 oncology-focused biotechnology company developing innovative RNA
interference (RNAi) therapies to treat solid tumors driven by KRAS
mutations, the most common oncogenic driver in human cancers. The
company's first-generation product, LODER™, has shown promising
EPS Data results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion
is also advancing its next-generation siRNA candidate, SIL-204,
2022 2023 2024 designed to target a broader range of KRAS mutations and showing
CQ1 N/A N/A (5.44) significant potential in preclinical studies. The company remains
CQ2 N/A N/A N/A committed to pushing the boundaries of therapeutic innovation in
oncology, with a focus on improving outcomes for patients with difficult-
CQ3 N/A N/A (0.82) to-treat cancers.
CQ4 N/A N/A (0.11)
CY N/A N/A (1.25) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 4.67
ROE (ttm) -116.66
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec

N
The Goldyne SJerusalem /A 9112001

Key Executives
CEO: Hadar, Ilan
CFO: Hadar, Mirit
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures